These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
250 related articles for article (PubMed ID: 19075074)
21. K13 mutations and pfmdr1 copy number variation in Plasmodium falciparum malaria in Myanmar. Win AA; Imwong M; Kyaw MP; Woodrow CJ; Chotivanich K; Hanboonkunupakarn B; Pukrittayakamee S Malar J; 2016 Feb; 15():110. PubMed ID: 26911145 [TBL] [Abstract][Full Text] [Related]
22. Artesunate-Amodiaquine and Artemether-Lumefantrine Therapies and Selection of Pfcrt and Pfmdr1 Alleles in Nanoro, Burkina Faso. Sondo P; Derra K; Diallo Nakanabo S; Tarnagda Z; Kazienga A; Zampa O; Valéa I; Sorgho H; Owusu-Dabo E; Ouédraogo JB; Guiguemdé TR; Tinto H PLoS One; 2016; 11(3):e0151565. PubMed ID: 27031231 [TBL] [Abstract][Full Text] [Related]
23. Selection of N86F184D1246 haplotype of Pfmrd1 gene by artemether-lumefantrine drug pressure on Plasmodium falciparum populations in Senegal. Mbaye A; Dieye B; Ndiaye YD; Bei AK; Muna A; Deme AB; Yade MS; Diongue K; Gaye A; Ndiaye IM; Ndiaye T; Sy M; Diallo MA; Badiane AS; Ndiaye M; Seck MC; Sy N; Koita O; Krogstad DJ; Nwakanma D; Ndiaye D Malar J; 2016 Aug; 15(1):433. PubMed ID: 27562216 [TBL] [Abstract][Full Text] [Related]
24. Temporal trends of molecular markers associated with artemether-lumefantrine tolerance/resistance in Bagamoyo district, Tanzania. Malmberg M; Ngasala B; Ferreira PE; Larsson E; Jovel I; Hjalmarsson A; Petzold M; Premji Z; Gil JP; Björkman A; Mårtensson A Malar J; 2013 Mar; 12():103. PubMed ID: 23506218 [TBL] [Abstract][Full Text] [Related]
25. Absence of in vivo selection for K13 mutations after artemether-lumefantrine treatment in Uganda. Balikagala B; Mita T; Ikeda M; Sakurai M; Yatsushiro S; Takahashi N; Tachibana SI; Auma M; Ntege EH; Ito D; Takashima E; Palacpac NM; Egwang TG; Onen JO; Kataoka M; Kimura E; Horii T; Tsuboi T Malar J; 2017 Jan; 16(1):23. PubMed ID: 28068997 [TBL] [Abstract][Full Text] [Related]
26. A randomized, open-label, comparative efficacy trial of artemether-lumefantrine suspension versus artemether-lumefantrine tablets for treatment of uncomplicated Plasmodium falciparum malaria in children in western Kenya. Juma EA; Obonyo CO; Akhwale WS; Ogutu BR Malar J; 2008 Dec; 7():262. PubMed ID: 19102746 [TBL] [Abstract][Full Text] [Related]
27. Selection of known Plasmodium falciparum resistance-mediating polymorphisms by artemether-lumefantrine and amodiaquine-sulfadoxine-pyrimethamine but not dihydroartemisinin-piperaquine in Burkina Faso. Somé AF; Séré YY; Dokomajilar C; Zongo I; Rouamba N; Greenhouse B; Ouédraogo JB; Rosenthal PJ Antimicrob Agents Chemother; 2010 May; 54(5):1949-54. PubMed ID: 20231394 [TBL] [Abstract][Full Text] [Related]
28. Prevalence of molecular markers of artemisinin and lumefantrine resistance among patients with uncomplicated Plasmodium falciparum malaria in three provinces in Angola, 2015. Ljolje D; Dimbu PR; Kelley J; Goldman I; Nace D; Macaia A; Halsey ES; Ringwald P; Fortes F; Udhayakumar V; Talundzic E; Lucchi NW; Plucinski MM Malar J; 2018 Feb; 17(1):84. PubMed ID: 29458380 [TBL] [Abstract][Full Text] [Related]
33. Montenegro M; Neal AT; Posada M; De Las Salas B; Lopera-Mesa TM; Fairhurst RM; Tobon-Castaño A Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28947476 [TBL] [Abstract][Full Text] [Related]
34. Molecular and pharmacological determinants of the therapeutic response to artemether-lumefantrine in multidrug-resistant Plasmodium falciparum malaria. Price RN; Uhlemann AC; van Vugt M; Brockman A; Hutagalung R; Nair S; Nash D; Singhasivanon P; Anderson TJ; Krishna S; White NJ; Nosten F Clin Infect Dis; 2006 Jun; 42(11):1570-7. PubMed ID: 16652314 [TBL] [Abstract][Full Text] [Related]
35. Prevalence of pfmdr1 alleles associated with artemether-lumefantrine tolerance/resistance in Maputo before and after the implementation of artemisinin-based combination therapy. Lobo E; de Sousa B; Rosa S; Figueiredo P; Lobo L; Pateira S; Fernandes N; Nogueira F Malar J; 2014 Aug; 13():300. PubMed ID: 25098280 [TBL] [Abstract][Full Text] [Related]
36. Therapeutic efficacy and effect on gametocyte carriage of an artemisinin and a non-based combination treatment in children with uncomplicated P. falciparum malaria, living in an area with high-level chloroquine resistance. Okafor HU; Shu EN; Oguonu T J Trop Pediatr; 2010 Dec; 56(6):398-406. PubMed ID: 20144932 [TBL] [Abstract][Full Text] [Related]
37. Baseline in vivo, ex vivo and molecular responses of Plasmodium falciparum to artemether and lumefantrine in three endemic zones for malaria in Colombia. Aponte S; Guerra ÁP; Álvarez-Larrotta C; Bernal SD; Restrepo C; González C; Yasnot MF; Knudson-Ospina A Trans R Soc Trop Med Hyg; 2017 Feb; 111(2):71-80. PubMed ID: 28460112 [TBL] [Abstract][Full Text] [Related]
39. Efficacy of artesunate plus amodiaquine versus that of artemether-lumefantrine for the treatment of uncomplicated childhood Plasmodium falciparum malaria in Zanzibar, Tanzania. Mårtensson A; Strömberg J; Sisowath C; Msellem MI; Gil JP; Montgomery SM; Olliaro P; Ali AS; Björkman A Clin Infect Dis; 2005 Oct; 41(8):1079-86. PubMed ID: 16163624 [TBL] [Abstract][Full Text] [Related]
40. Decreasing pfmdr1 copy number in plasmodium falciparum malaria heightens susceptibility to mefloquine, lumefantrine, halofantrine, quinine, and artemisinin. Sidhu AB; Uhlemann AC; Valderramos SG; Valderramos JC; Krishna S; Fidock DA J Infect Dis; 2006 Aug; 194(4):528-35. PubMed ID: 16845638 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]